If there was a deal it clearly did not entail the issuance of additional shares to ARYC, Linn notes that the OS is still 215 million !! Also if an agreement was reached, it is a material event and AVDX should have filed an 8K!!
I also noted that his discussion of OVADx was very perfunctory and he never once called the ovarian cancer test by it's name "OVADx"
My take: no deal was struck and either OVADx is headed back to ARYC or litigation is pending!!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.